Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Josephson F et al. | CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. | 2008 | Eur. J. Clin. Pharmacol. | pmid:18458892 |
Hole K et al. | Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. | 2017 | Eur. J. Clin. Pharmacol. | pmid:27975131 |
Mao J et al. | Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. | 2017 | Drug Metab. Rev. | pmid:27718639 |
Ishida T et al. | Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. | 2016 | Drug Metab. Pharmacokinet. | pmid:27236640 |
Naito T et al. | CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. | 2015 | Drug Metab. Pharmacokinet. | pmid:26654672 |
Björkhem-Bergman L et al. | Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study. | 2013 | Drug Metab. Dispos. | pmid:23386704 |
Peters J et al. | Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. | 2011 | Drug Metab. Dispos. | pmid:21690264 |
Suzuki Y et al. | Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. | 2014 | Drug Metab. Dispos. | pmid:24135442 |
Li K et al. | 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys. | 2014 | Drug Metab. Dispos. | pmid:24595680 |
Björkhem-Bergman L et al. | Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. | 2013 | Drug Metab. Dispos. | pmid:23674608 |